Cynosure / Jeisys Medical
Potenza
A radiofrequency microneedling platform with multiple monopolar/bipolar and insulated/non-insulated tip configurations.
Fractional radiofrequency microneedlingReviewed 7/30/2026Source recorded
At a glance
| Primary purpose | Dermatologic and general surgical procedures for electrocoagulation and hemostasis under the US clearance; advertised cosmetic protocols go beyond that narrow cleared wording. |
|---|---|
| Mechanism | Microneedle electrodes enter tissue and deliver monopolar or bipolar radiofrequency through selected insulated or non-insulated tip configurations, producing controlled coagulation. |
| When results appear | Remodelling, if achieved, develops over weeks to months rather than immediately. |
| Typical sessions | Often used in a series, but no universal session count is established by the US clearance. |
| Downtime | Redness, swelling, tenderness, pinpoint bleeding, crusting, and temporary needle marks can occur. |
| Reversibility | Not reversible; thermal and needle injury cannot be withdrawn. |
| Documented risks | Pain, bleeding, infection, burns, scarring, pigment change, fat loss, contour change, and nerve injury; the FDA's 2025 RF-microneedling safety communication applies to the procedure category. |
| Most common disappointment | Many public claims describe cosmetic outcomes that are not the same as the device's narrow US cleared indication. |
| Common marketing misconception | The number of modes or tips does not by itself prove superior results or safety. |
| What varies by provider | Tip selection, insulated status, monopolar or bipolar mode, depth, energy, pulse duration, passes, overlap, anesthesia, and infection control. |
| Skin-tone considerations | RF is not melanin-targeted, but burns and post-inflammatory pigment change remain possible; no equivalence across all skin tones is inferred from clearance. |
| When this treatment may not be appropriate | When active infection, impaired healing, implanted-device concerns, or unwillingness to accept thermal injury makes treatment unsuitable; exact IFU screening is required. |
| United States regulatory status | FDA 510(k)-cleared under K192545 for dermatologic and general surgical procedures for electrocoagulation and hemostasis. The clearance should not be rewritten as an FDA-cleared wrinkle or skin-tightening indication. |
| Canadian regulatory status | Health Canada MDALL lists Potenza Fractional RF Microneedle Electrosurgical Unit under active Class III licence 106699. |
| Evidence status | High for device identity, mechanism, and regulatory boundaries; limited for product-specific comparative efficacy, session count, and durability. |
Sources
- FDA 510(k) Summary K192545: PotenzaFDA 510(k) summary · regulatory-primary · supports 17 profile fields
- FDA Safety Communication: Potential Risks with Certain Uses of RF MicroneedlingFDA safety communication · regulatory-primary · supports 7 profile fields
- Health Canada MDALL: Jeisys Potenza licenceHealth Canada MDALL · regulatory-primary
- Potenza Physician Brochureofficial manufacturer technical information · manufacturer-primary
Related comparisons
See average treatment prices near you
Enter a US ZIP code or Canadian postal code to check our stored estimate for the surrounding market.